Northern epilepsy

Northern epilepsy, also known as progressive epilepsy with mental retardation (EPMR) or CLN8 disease, Northern epilepsy variant, is a rare inherited neurodegenerative disorder belonging to the neuronal ceroid lipofuscinoses (NCL) family of diseases. It was first identified in families from the Kainuu region of northern Finland, giving the condition its name. The disease is caused by mutations in the CLN8 gene, which encodes a transmembrane protein involved in lipid transport and metabolism. Dysfunction of this protein leads to abnormal accumulation of ceroid lipofuscin within cells, particularly affecting the central nervous system. The condition typically presents between ages 5 and 10 years with generalized tonic-clonic seizures. Initially, seizures may be infrequent but tend to increase in frequency during adolescence before stabilizing or decreasing in adulthood. A hallmark feature is progressive cognitive decline (intellectual disability) that begins approximately 2 to 5 years after seizure onset and worsens over time. Affected individuals experience progressive loss of previously acquired cognitive and motor skills. Visual impairment may also occur, though it is generally less prominent than in other NCL subtypes. Brain imaging typically reveals progressive cerebral and cerebellar atrophy. There is currently no cure for Northern epilepsy. Treatment is symptomatic and supportive, focusing primarily on seizure management with antiepileptic medications, though seizures may become refractory to treatment over time. Supportive therapies including physical therapy, occupational therapy, speech therapy, and educational support are important components of care. Life expectancy is reduced, with many patients surviving into their 40s to 60s. Genetic counseling is recommended for affected families.

Common questions about Northern epilepsy